Exclusive: Aviv Regev talks three years of leading Genentech’s research, the future of AI, and not making Nobel predictions
SOUTH SAN FRANCISCO — In 2020, Aviv Regev ended an esteemed 14-year run at the Broad Institute to jump into the drug industry, becoming Genentech’s head of research and early development.
The 52-year-old computational biologist has pioneered the field of single-cell genomics, which studies individual cells at massive scale, weaving together biology and computer science. Now, Regev is building what she calls the “lab in a loop” at Genentech, where experimental and computational scientists train and work alongside each other.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.